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Growth arrest-specific gene 6 (Gas6), identified in 1995, acts as the ligand to the Axl/Tyro3 family of tyrosine kinase receptors and
exerts mitogenic activity when bound to these receptors. Overexpression of the Axl/Tyro3 receptor family has been found in breast,
ovarian and lung tumours. Gas6 is upregulated 23-fold by progesterone acting through the progesterone receptor B (PRB). Recently,
Gas6 has been shown to be a target for overexpression and amplification in breast cancer. Quantitative real-time PCR analysis was
used to determine the levels of Gas6 mRNA expression in 49 primary breast carcinomas. Expression of PRB protein was evaluated
immunohistochemically with a commercially available PRB antibody. The results showed a positive association between PRB protein
and Gas6 mRNA levels (P¼0.04). Gas6 correlated positively with a number of favourable prognostic variables including lymph node
negativity (P¼0.0002), younger age at diagnosis (P¼0.04), smaller size of tumours (P¼0.02), low Nottingham prognostic index
scores (P¼0.03) and low nuclear morphology (P¼0.03). This study verifies for the first time the association between PRB and Gas6
in breast cancer tissue.
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In 1993, the growth arrest-specific gene 6 (Gas6) was first
described (Manfioletti et al, 1993) and, in 1995, human Gas6 was
mapped to chromosome 13q34 by fluorescence in situ hybridisa-
tion (Saccone et al, 1995). The Gas6 protein has 44% identity to
human protein S, a vitamin K-dependent negative coregulator in
the blood coagulation pathway. However, Gas6 lacks the thrombin
cleavage site, typical of vitamin K-dependent coagulation factors.
Similar to protein S, Gas6 is composed of defined structural motifs
comprised of a gamma-carboxylated amino terminus (Gla
domain), four tandem repeats of epidermal growth factor (EGF)-
like domains and a large carboxy-terminal domain with similarity
to the sex hormone-binding globulin (SHBG) (Manfioletti et al,
1993).
Gas6 has been identified as a ligand for the Axl/Tyro3 family of
receptor tyrosine kinases (RTK), including Axl, Tyro3 (also known
as Sky) and Mer (Varnum et al, 1995). Gas6 binds to these
receptors with binding affinities in the order of Axl4Tyro34Mer.
Once bound, Gas6 induces receptor phosphorylation in a dose-
responsive manner (Chen et al, 1997).
In murine cell lines, recombinant human Gas6 protein interacts
with the extracellular domain of the Axl-RTK, leading to either
increased receptor kinase activity and activation of the mitogen-
activated protein (MAP) kinase pathway (Bellosta et al, 1997), or
the phosphatidyl-inositol (PI)3-kinase pathway. Gas6 thereby
exerts mitogenic activity in cell lines, and furthermore has been
shown to initiate coordinated entry into the S phase of the cell
cycle, when bound to endogenous Axl (Goruppi et al, 1996).
Overexpression of receptors for Gas6 belonging to the Axl/Tyro3
family had been reported in human mammary tumours, leukaemia
and lung cancers (Crosier et al, 1995; Berclaz et al, 2001; Shieh
et al, 2005).
Mouse studies have shown that Gas6 is a platelet response
amplifier that plays a significant role in pathological thrombosis,
and that Gas6-neutralising antibodies inhibit platelet aggregation
in vitro (Angelillo-Scherrer et al, 2001). Furthermore, when the
Gas6 receptor is blocked, initial platelet aggregation does occur,
but stabilisation of platelet aggregates is impaired and mice are
protected against life-threatening thrombosis (Angelillo-Scherrer
et al, 2005). This inhibition preventing thrombus does not increase
bleeding, and so makes Gas6 inhibition an ideal therapeutic option
in thrombotic disorders. Recent publications have confirmed that
all three RTKs (Axl, Tyro3 and Mer) are present on human
platelets and that Gas6 expression is high in blood (Gould et al,
2005; Balogh et al, 2005).
In breast cancer cell lines, Gas6 has been demonstrated to be
upregulated greater than 23-fold by progesterone acting through
the progesterone receptor B (PRB) (Richer et al, 2002). In 2001, it
was shown that overexpression of Gas6 resulted in the stabilisation
of b-catenin, an E-cadherin-anchoring protein, in cultured
mammalian cell lines (Goruppi et al, 2001). This has implications
for the development of features of the epithelial-mesenchymal
transition (EMT) phenotype, a well-recognised phenomenon
resulting in increased tumour invasiveness, proliferation and
cancer cell motility. Membrane staining of the receptor for Gas6,
Axl, has been reported to be higher in cancerous tissue than in the
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snormal breast (Berclaz et al, 2001). Moreover, the Gas6 locus has
recently been described as a target for amplification in mouse
models of breast cancer and in human breast cancer (Abba et al,
2007).
The current study was undertaken to validate expression of Gas6
in primary breast carcinomas and to evaluate the clinical relevance
of this PRB-regulated gene in breast carcinogenesis. So far, this
association has not been investigated in human breast tissue. To
this end, we determined the mRNA expression levels of Gas6 in
primary breast tumours using quantitative real-time PCR,
correlated PRB protein and Gas6 mRNA levels in this cohort and
examined the relationship of Gas6 to a number of clinical variables
(eg risk factors, surgical treatment and histopathological profiles)
and clinical outcome.
MATERIALS AND METHODS
Ethical issues and details of the tissue cohort used in this
study
Fresh human breast tumour surgical specimens were collected
prospectively in the Mater Misericordiae and Mater Private
Hospitals (Dublin, Ireland). The experiments were carried out
with the approval of the Mater Hospital Ethics Committee, and all
patients participating in this study gave full and informed consent.
Samples were taken from mastectomy or wide local excision
surgical specimens under the supervision of a pathologist. Fresh
tissue samples were snap frozen and stored at  701C. These
specimens were divided into two, one for RNA extraction and one
for fixing and paraffin embedding to allow haematoxylin- and
eosin-stained histological examination. There were a total of 49
specimens from patients with primary breast carcinomas. Clinical
information was collected on all patients who donated a sample of
tissue for the study. The pathologist associated with the study
reviewed all the cases and evaluated independently a number of
histological characteristics of the tissue specimens including
grading subtypes (mitotic index, tubule formation, nuclear
pleomorphism), presence of lymphocytic infiltration and presence
of pushing or infiltrating margins. Follow-up data from outpatient
clinic assessments and general practitioners were recorded and a
numerically coded database was then constructed for the purpose
of statistical analysis. Table 1 shows the clinicopathological
characteristics of the cohort.
Extraction of total RNA and random hexamer-primed
cDNA synthesis
Total RNA was extracted from the frozen tissues using Trizolt
(MRC Inc., Cincinnati, OH, USA) according to the manufacturer’s
instructions. RNA concentrations were estimated from spectro-
photometer absorbance readings of 260 and 280nm. Samples were
subjected to DNase treatment (Invitrogen Life Technologies Inc.,
Renfrew, Strathclyde, UK) to eliminate any possible DNA
contamination. Single-stranded cDNA was subsequently generated
using random hexamer-primed sequences and Superscriptt II
(Invitrogen Life Technologies Inc.) methodology. cDNA was
synthesised at 421C for 2h followed by inactivation of the enzyme
at 701C for 15min. Negative controls with the omission of the
reverse transcriptase were set up for all samples. Resultant cDNA
samples were stored at  201C.
Real-time LightCycler
t quantitative Gas6 PCR
LightCyclert real-time PCR was used to quantify Gas6. Ten
microlitres of master SYBR Green (Qiagen, Crawley, West Sussex,
UK) was mixed with 6ml of RNase-free H2O, 1ml of each primer
and 2ml of cDNA template and subsequently loaded into each
capillary. All quantitative assays were based on serially diluted
solutions of target-specific PCR product for Gas6 and endogenous
18S rRNA (Taqmant Ribosomal RNA Control Reagents; Applied
Biosystems, Foster City, CA, USA). Primer sequences for 18S were
obtained from on-line primer design software Primer3design
(http://frodo.wi.mit.edu) (18S FWD 50-AGGGTTCGATTCCGGAG-30,
18S REV 50-ACCAGACTTGCCCTCC-30) and those for Gas6 were
designed with Quantiprobe design software (www.qiagen.com/goto/
assays) (Gas6 FWD 50-GTAGCTTCCACTGTTCCT-30,G a s 6R E V
50-GCGCACTCGTCTATGTCTT-30). Cycling conditions for Gas6 were
951C for 15min followed by 40 cycles of 941C for 15s, 581Cf o r2 0s
and 721Cf o r1 2s .
Each experiment was set up using a standard curve, with each
quantitative point represented in triplicate. Test cDNA expression
levels were generated from the standard curve using the in-built
LightCyclert second derivative maximum software for quantifica-
tion. Quantitative normalisation of Gas6 in each sample was
performed using endogenous 18S rRNA as an internal control.
Subsequently, Gas6 mRNA levels are shown as amol per 1ng
endogenous 18S rRNA from the median of triplicate samples.
PRB immunohistochemistry
Serial 5mm sections were prepared from each of the corresponding
formalin-fixed paraffin-embedded tumour blocks that had been
identified pathologically. Immunohistochemical evaluation of the
PRB protein was carried out using the commercially available
lyophilised monoclonal antibody (NCL-PGR-B) clone SAN27 from
Novocastra, (Newcastle Upon Tyne, UK) with antigen retrieval
using Trilogy (20 ). The primary antibody, PRB, was applied. A
biotinylated secondary antibody was then added, followed by an
avidin and biotinylated horseradish peroxidase macromolecular
complex (Vectastain Universal Elite ABC kit, Vector Laboratories,
Table 1 Histopathological profiles of patients in the Gas6 study
Patient attribute Number Percentage
Total primary breast cancers 49 100
Mean age (range) 60 years (33–87 years)
Cancer type
Invasive ductal 42 86
Invasive lobular 1 2
Mixed 6 12
Tumour size
o20mm 4 8
20–50mm 33 67
450mm 12 25
Tumour grade (Elston and Ellis, 1991)
I1 2
II 28 57
III 20 41
Lymph node status
01 9 3 9
1–3 15 30.5
43 15 30.5
Nottingham prognostic index (Blamey, 1996)
o2.4, excellent 0 0
2.5–3.4, good 5 10
3.5–4.4, moderate I 13 27
4.5–5.4, moderate II 11 22
45.4, poor 20 41
HER-2/neu status
Positive 3 6
Negative 13 27
Unknown 33 67
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(ChemMate Dako Envisiont Kit), sections were counterstained
and quantified. A positive result was one where 410% of the cells
exhibited nuclear staining.
Statistical analyses
SAS version 8 (SAS Institute Inc., Cary, NC, USA) was used for all
statistical analyses. The w
2 test was used for comparison of
proportions, correlation coefficients were calculated to determine
the strength of the relationship between two continuous variables
and the t-test, Wilcoxon rank sum test or analysis of variance was
used as appropriate to compare groups. Logistic regression was
performed to adjust for confounders, where the outcome variable
was binary. Multiple regression was carried out to adjust for
confounders where the outcome variable was continuous. Initially,
all of the standard clinicopathological variables were looked at in
univariate analyses to identify those variables that were signifi-
cantly associated with disease-free interval (DFI) and overall
survival (OS). In addition, the laboratory results for Gas6 mRNA
were similarly analysed. The clinicopathological and laboratory
variables found to be significant in the univariate analyses (lymph
node status, ERa, stage, CEA levels and CA 15.3 levels for DFI;
(lymph node status, Nottingham prognostic index (NPI), stage, CA
15.3, size and margins for OS) were subsequently used in the Cox
multivariate model to identify those with independent significance
for both the DFI and OS outcomes.
RESULTS
Quantitative real-time PCR results for Gas6
The resultant ratios of Gas6 mRNA to endogenous ribosomal 18S
mRNA are shown in Figure 1. All the specimens were positive for
log Gas6
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Figure 1 Quantitative real-time PCR expression levels of Gas6 in primary breast carcinomas.
Table 2 Clinical variables statistically associated with Gas6
Gas6 mRNA
Variable o2.2 10
6 42.2 10
6 P-value
PRB IHC (n¼30)
Negative (p10%) 10 (77%) 3 (23%) 0.04
Positive (410%) 7 (35%) 11 (65%)
oMean 4Mean
Lymph node metastases (n¼49)
Average (s.d.) 4.219 (5.35) 0.5 (1.07) 0.0002
(s.e.m.) (0.84) (0.378)
oMean 4Median
Nuclear morphology (NM) (n¼38)
NM¼1o r2( n¼7) 4 (57%) 3 (43%) 0.03
NM¼3( n¼31) 28 (90.3%) 3 (9.7%)
oMedian 4Median
Age (n¼49)
p50 years (n¼24) 2 (20%) 8 (80%) 0.04
450 years (n¼25) 22 (56%) 17 (44%)
Margin type (n¼38)
Infiltrating (n¼19) 13 (65%) 7 (35%) 0.05
Pushing (n¼19) 6 (33%) 12 (67%)
0 oMean 4Mean
Size (n¼49)
Continuous variable
Mean (s.d.) 54.83 (29.87) 37.19 (18.9) 22.33 (5.8) 0.02
NPI (n¼49)
Continuous variable
Mean (s.d.) 5.76 (1.35) 5.12 (1.18) 3.94 (0.59) 0.03
IHC¼immunohisto chemistry; NPI¼Nottingham prognostic index; PRB¼progesterone B.
Gas6 expression in breast cancer
O Mc Cormack et al
1143
British Journal of Cancer (2008) 98(6), 1141–1146 & 2008 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sribosomal 18S; however, six samples were negative for Gas6 mRNA
expression and there was a wide variation in the Gas6 mRNA levels
in the primary tumour cohort.
Association of Gas6 results with PRB profiles
When the Gas6 mRNA results were examined in relation to the
PRB immunohistochemical profiles, there was a positive associa-
tion between PRB immunohistochemistry (positive410%) and
Gas6 mRNA levels in curatively resected cancers (stage 4 disease
was omitted) (Table 2).
Comparison of Gas6 results with clinical variables
Gas6 mRNA expression was inversely associated with the presence
of lymph node metastases. The majority of younger women (80%)
had high Gas6 mRNA levels, whereas the majority of older women
(56%) expressed low levels of Gas6 mRNA. There was a significant
inverse association between tumour size and Gas6 expression.
Larger tumours (average size¼38mm) were associated with low
Gas6 levels and smaller tumours (average size¼22mm) were
associated with high Gas6 levels. When Gas6 expression was
compared to the NPI, there was an inverse correlation. Tumours
with low Gas6 levels were found to have high NPI scores
(average¼5.1, poor prognosis) and those with high Gas6
expression had low NPI scores (average¼3.94, moderate 1
prognosis). This association held true when adjusted for con-
founding variables such as tumour size. In the low Gas6 group,
90.3% of the samples had a nuclear morphology of 3. The tumour
group with low Gas6 levels was found to have infiltrating margins
on histology, whereas the group with high Gas6 levels was found to
have pushing margins (Table 2).
The mean duration of follow-up was 3.5 years, with a range of 21
days to 5.2 years. With regard to DFI, 12 patients (24%) developed
a recurrence during the follow-up period of this cohort. At the end
of the follow-up, 36 (74%) were alive and well, 3 (6%) were alive
with breast cancer recurrence, 9 (18%) had died from breast cancer
and 1 person (2%) had died from another cause. Gas6 mRNA levels
were not independently associated with DFI or OS in this cohort by
univariate or multivariate analysis (Figure 2A and B). Significant
variables for DFI included lymph node metastases (P¼0.02), ERa
immunohistochemistry (P¼0.03), stage (P¼0.003), CEA
(P¼0.01) and CA 15.3 (P¼0.05) (Table 3). The variable that
remained significant for DFI after multivariate analysis was
stage. Other variables were nonsignificant. In the survival
analyses, significant variables were lymph node status (P¼0.01),
NPI (P¼0.003), stage (P¼0.002), CA 15.3 (P¼0.05), tumour
size (P¼0.04) and tumour margins (P¼0.05) (Table 4). Similar to
DFI, stage was the only independent predictor of OS in this
analysis.
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Figure 2 Kaplan–Meier curves. (A) Gas6 mRNA levels (4median, omedian) and DFI. (B) Gas6 mRNA levels (4median, omedian) and OS.
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Gas6 expression correlated significantly with PRB expression in
this cohort (P¼0.04). This is the first documented positive
relationship between PRB and Gas6 in human breast tumours and
extends the previous work of Richer et al (2002) on breast cancer
cell line. Gas6 has displayed mitogenic activity in cell lines;
however, in our cohort, Gas6 was associated with favourable
prognostic markers including smaller tumour size (P¼0.02),
decreased levels of lymph node metastases (P¼0.0002) and lower
nuclear morphology (P¼0.03). Gas6-positive tumours were
associated with pushing margins on histological assessment.
Pushing margins have been found in BRCA1 mutation-positive
patients with breast cancer (Lakhani, 1999). Interestingly, a recent
publication has cited an association between BRCA1 mutation and
increased progesterone receptor signalling (Ma et al, 2006). This
would be in keeping with our findings.
As the association between PRB and Gas6 had not been
validated previously, this study has the potential to generate
further work in this area. At present, the only commercially
available antibodies for growth arrest-specific proteins (including
Gas1 and Gas6) are polyclonal (produced by Santa Cruz
Biotechnology Inc.). To date, specificity of this antibody has been
problematic on western blot analysis.
Gas6 is an attractive target for molecular manipulation, as it is
the ligand of the Axl tyrosine kinase receptor, which has previously
been shown to be overexpressed in a subset of breast carcinomas
(Berclaz et al, 2001). Moreover, expression of both Gas6 and Axl is
increased in ovarian, endometrial and prostate carcinomas (Sun
et al, 2003, 2004; Sainaghi et al, 2005), confirming expression of
these potential targets in hormone-responsive tumours.
Studies focusing on the role of Gas6 in coagulation pathways
have shown that Gas6 is a platelet response amplifier that plays a
significant role in pathological thrombosis. These studies have
progressed and inhibition of Gas6 or the Axl receptor has been
achieved in mouse models. When the receptor is blocked, initial
platelet aggregation does occur, but stabilisation of platelet
aggregates is impaired and mice are protected against life-
threatening thrombosis (Angelillo-Scherrer et al, 2005). Notably,
when Gas6 was inhibited, thrombus was prevented; however, there
was no increase in bleeding. This makes Gas6 inhibition an ideal
therapeutic option for thrombosis.
Similar to most cancer patients, breast cancer patients are at an
increased risk of developing thrombosis. In addition, there is an
increased risk of thrombo-embolic events such as stroke,
pulmonary embolism and deep vein thrombosis, when using
tamoxifen with cytotoxics. Hypothetically, an agent that targets
Gas6 or Axl would benefit women with breast cancer by blocking a
downstream effector of progesterone and potentially decreasing
thrombosis, without causing increased bleeding. Theoretically,
such a strategy could be used with conventional anti-oestrogen
agents such as tamoxifen and aromatase inhibitors.
Further work examining the role of Gas6 as an anti-hormone
treatment in breast cancer with the additional characteristic of it
preventing thrombosis is an attractive area for future investigations.
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Table 3 Significant variables associated with disease free interval on
univariate analysis
Variable P-value Hazard ratio
Lymph node status
0— 1
1–3 0.06 3.1
43 0.02 3.8
Lymph node status
Positive 0.02 3.5
Negative — 1
ERa immunohistochemistry
Positive 0.03 0.4
Negative — 1
Stage
I— 1
II 0.09 2.7
III+IV 0.003 6
CEA
Positive (45) 0.01 4.3
Negative (p5) — 1
CA 15.3
Positive (440) 0.05 4.3
Negative (p40) — 1
Gas6 mRNA
Above the mean 0.99 0
Below the mean — 1
Gas6 mRNA
Above the median 0.08 0.3
Below the median — 1
Table 4 Significant variables associated with survival on univariate
analysis
Variable P-value Hazard ratio
Lymph nodes
0— 1
1–3 0.1 3.4
43 0.01 7.1
Lymph nodes
Positive compared to negative 0.03 5
NPI (Blamey, 1996)
Continuous variable 0.003 1.9 per unit increase in NPI
Stage
I— 1
II 0.22 2.6
III+IV 0.002 11.4
CA 15.3
Positive (440) 0.05 11.4
Negative (p40) — 1
Size
450mm 0.04 2.9
o50mm — 1
Margins
o10 0.05 0.13
410 — 1
Gas6 mRNA
Above the mean 0.99 0
Below the mean — 1
Gas6 mRNA
Above the median 0.15 0.36
Below the median — 1
NPI¼Nottingham prognostic index.
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